Visibuilt, a Danish BioTech company developing biobased alternatives to conventional carbon-intensive construction binders, has secured €3.34 million in Seed funding to move from lab pilots towards market validation and industry tests. The round was co-led by EIFO and Unconventional Ventures followed by Proptechfonden and backed again by earlier investor EMDFonden.
David Cendon Garcia
Visibuilt, a Danish BioTech company developing biobased alternatives to conventional carbon-intensive construction binders, has secured €3.34 million in Seed funding to move from lab pilots towards market validation and industry tests.
The round was co-led by EIFO and Unconventional Ventures followed by Proptechfonden and backed again by earlier investor EMDFonden.
“Closing this Seed round is an important milestone for Visibuilt. It enables us to mature our technical platform, validate our solution at a larger scale, and take the next steps towards the market,” says Line Kloster Pedersen, CEO and founder of Visibuilt.
Visibuilt’s Seed round follows approximately €32 million in funding reported by EU-Startups during 2026 for companies developing low-carbon, biobased, waste-derived or circular construction materials and related infrastructure.
These included Finland’s Carbonaide, which raised €3.7 million for CO₂-curing technology; Germany’s Co-reactive, with €6.5 million for CO₂ mineralisation; London-based Cocoon Carbon, which secured €13 million to produce cement substitutes from steel slag; Bristol-based Mykor, which raised €4.6 million for biotechnology-derived construction materials; and Circular11 and MAECONOMY, which secured €2.7 million and €1.5 million respectively for waste-based products and circular-material infrastructure.
Including Visibuilt, the disclosed funding across these 2026 announcements totals approximately €35.34 million.
“Concrete and asphalt production are among the largest sources of CO₂ emissions globally. If we are to truly reduce emissions, it requires new solutions in heavy industries. Visibuilt has an approach that could become an important piece of that transition,” says Sara Sande, Managing Director, Partner and Head of Direct Thematic Venture at EIFO.
Founded in 2022, Visibuilt is a BioTech company developing a mycelium-based binder solution for the construction and infrastructure industries. Founded by Line Kloster Pedersen and Oleksii Rebrov, the company combines biotechnology and materialscience to create lower-carbon alternatives to conventional construction materials.
The binder technology, visiBINDER, is a mycelium-based binder designed for paving and infrastructure applications.
The technology is designed to offer a less energy intensive solution for paving materials while meeting the durability and performance requirements of outdoor applications.
“At Unconventional Ventures, we look for companies where the impact case and the commercial case are structurally identical. Visibuilt is that company. Every tonne of visiBINDER placed in a paving application displaces a tonne of fossil binder, generates royalty revenue, and reduces the embedded carbon of the infrastructure it goes into.
“Line has built active industrial testing relationships with Denmark’s leading concrete paver manufacturer and Copenhagen Municipality within two years of founding – without a finished production setup and without a fully derisked product. That is an unusual execution signal for a HardTech founder at this stage, and it is why we co-led,” says Thea Messel, General Partner, Unconventional Ventures
The new funding will allow Visibuilt to expand testing and validation activities, establish the production setup required for larger-scale trials, and strengthen the team with additional technical and commercial expertise.
These activities will support the company’s ambition to demonstrate the technology in real-world applications and prepare for future market introduction.
